CSIMarket Company Name, Ticker, Customers, else..
 
Bionexus Gene Lab Corp   (NASDAQ: BGLC)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $1.4500 $-0.02 -1.361%
Day's High: $1.4500000476837158 Week Perf: -2.68 %
Day's Low: $ 1.39 30 Day Perf: -8.23 %
Volume (M): 800 52 Wk High: $ 6.10
Volume (M$): $ 0 52 Wk Avg: $3.07
Open: $1.39 52 Wk Low: $1.07



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 2
 Employees 19
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Bionexus Gene Lab Corp is a biotechnology company that focuses on genetic research and development. The company specializes in genetic testing, analysis, and sequencing for various applications such as personalized medicine, drug discovery, and agricultural biotechnology. The lab utilizes advanced technologies and techniques to understand genetic variations and their impact on human health and the environment. Bionexus Gene Lab Corp aims to provide valuable insights and innovative solutions through its genetic research to improve health outcomes and promote sustainable practices.


   Company Address: Unit A-28-7, Level 28, Tower A Kuala Lumpur 59000
   Company Phone Number: 241 6898   Stock Exchange / Ticker: NASDAQ BGLC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CFOR   -0.02%    
FTRE   -5.9%    
A   -1.94%    
BIO   -0.41%    
ILMN        1.22% 
MRNA        5.48% 
• View Complete Report
   



Financing Agreement

Biotechnology Meets Renewable Energy: BioNexus Gene Lab Corp Expands Horizons with Protech Builders in Biogas Initiatives

Published Wed, Sep 25 2024 3:32 PM UTC

Biotechnology Meets Renewable Energy: BioNexus Gene Lab Corp. Expands Horizons with Protech Builders in Biogas InitiativesIn a notable convergence of biotechnology and renewable energy sectors, BioNexus Gene Lab Corp. (NASDAQ: BGLC) has formally announced a strategic teaming agreement with Protech Builders Sdn. Bhd. to develop biogas power plants. This partnership signifies ...
Product Service News

BioNexus Gene Lab Corp. Partners with VITARRAY Global to Enhance mRNA Services Amidst Market Challenges

Published Fri, Sep 13 2024 4:05 PM UTC

In a significant development within the biotechnology sector, BioNexus Gene Lab Corp. (NASDAQ: BGLC) has announced a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. a company based in Singapore. The partnership, formalized on September 14, 2024, focuses on providing dynamic mRNA gene detection services tailored to the Southeast Asian market. This collaboration...
Partnership

BioNexus Gene Lab Corp. Forms Strategic Partnership Amidst Stock Struggles

Published Thu, Sep 12 2024 5:23 PM UTC

In a significant move to enhance its offerings in cancer screening, precision medicine, and preventative healthcare, BioNexus Gene Lab Corp. has entered into a strategic partnership with Shenzhen Rongguang Group. This memorandum of understanding (MOU) is poised to bolster innovative healthcare solutions, aiming to capitalize on the growing demand for advanced diagnostic tech...
Financing Agreement

BioNexus Gene Lab Corp Sets the Stage for Growth with Chemrexns Investment in Cutting-Edge Color Paste Production
n,

Published Wed, Sep 11 2024 3:05 PM UTC

nnBioNexus Gene Lab Corp: Strategic Investments and Operational Improvements Position for Future Growthnn
In a notable move that showcases its commitment to growth and innovation, BioNexus Gene Lab Corp (NASDAQ: BGLC) announced on September 11, 2024, that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), will be pioneering the production of high-quality color past...
Financing Agreement

nnBioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd, Aiming for Growth Amid Declining Financial Performance,

Published Mon, Aug 26 2024 4:15 PM UTC


KUALA LUMPUR, Malaysia On August 27, 2024, BioNexus Gene Lab Corp. (NASDAQ: BGLC) announced the closing of a significant investment worth RM 1 million (approximately USD 228,000) in Ascension Innovation Sdn Bhd (AISB), a forward-thinking healthcare technology company based in Malaysia. This investment, facilitated through BGLC’s wholly-owned subsidiary MRNA Scientif...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.12
Price to Sales (Expected) -
Price to Book 0.45
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.72
Working Capital Ratio 6.75
Leverage Ratio (MRQ) 0.12
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.32 $
Revenues (TTM) 1.29 $
Cash Flow (TTM) 0.36 $
Cash 1.92 $
Book Value 3.22 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 164,557
Net Income per Employee (TTM) -135,533
Receivable Turnover Ratio (TTM) 5.89
Inventory Turnover Ratio (TTM) 3.65
Asset Turnover Ratio (TTM) 0.35

Profitability Ratios Current
Gross Margin (MRQ) 17.05 %
Operating Margin (MRQ) -370.81 %
Net Margin (MRQ) -376.14 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Bionexus Gene Lab's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.